ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

ROSGQ Rosetta Genomics Ltd (CE)

0.0001
0.00 (0.00%)
14 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Rosetta Genomics Ltd (CE) USOTC:ROSGQ OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.0001 0.00 01:00:00

Report of Foreign Issuer (6-k)

10/04/2018 3:01pm

Edgar (US Regulatory)


 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of April 2018

 

Commission File Number 001-33042

 

ROSETTA GENOMICS LTD.

(Translation of registrant’s name into English)

 

10 Plaut Street, Science Park

Rehovot 76706, Israel

(Address of Principal Executive Offices) 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-For Form 40-F:

Form 20-F x              Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):         ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):         ¨

 

 

 

 

 

Rosetta Genomics Ltd.

 

On April 10, 2018, Rosetta Genomics Ltd., published a letter to shareholders urging shareholders to vote in favor of the proposed merger with Genoptix, Inc. A copy of the letter to shareholders is filed as Exhibit 99.1 to this Form 6-K and incorporated by reference herein.

 

 

 

 

Exhibits

 

Exhibit

Number

  Description of Exhibit
     
99.1   Letter to shareholders dated April 10, 2018.

 

 

 

 

Signatures

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ROSETTA GENOMICS LTD.
   
Date: April 10, 2018  By:  /s/ Ron Kalfus
   

Ron Kalfus

Chief Financial Officer

 

 

 

1 Year Rosetta Genomics (CE) Chart

1 Year Rosetta Genomics (CE) Chart

1 Month Rosetta Genomics (CE) Chart

1 Month Rosetta Genomics (CE) Chart

Your Recent History

Delayed Upgrade Clock